Scinai Immunotherapeutics Ltd. (SCNI) Earnings History
Annual and quarterly earnings data from 2009 to 2025
Loading earnings history...
SCNI EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SCNI Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | -202.3% | -575.3% | -633.6% |
| 2024 | -88.1% | -1312.8% | 728.9% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export SCNI earnings history in CSV or JSON format
Free sign-in required to download data
Scinai Immunotherapeutics Ltd. (SCNI) Earnings Overview
As of May 8, 2026, Scinai Immunotherapeutics Ltd. (SCNI) reported trailing twelve-month net income of $4M, reflecting -160.0% year-over-year growth. The company earned $2.57 per diluted share over the past four quarters, with a net profit margin of -633.6%.
Looking at the long-term picture, SCNI's historical earnings data spans multiple years. The company achieved its highest annual net income of $5M in fiscal 2024.
Scinai Immunotherapeutics Ltd. maintains positive profitability with a gross margin of -202.3%, operating margin of -575.3%, and net margin of -633.6%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including NVAX (-$88M net income, 39.2% margin), DYAI (-$7M net income, -166.2% margin), IBIO (-$25M net income, -4594.3% margin), SCNI has room to improve margins relative to the peer group. Compare SCNI vs NVAX →
SCNI Earnings vs Peers
Earnings metrics vs comparable public companies
SCNI Historical Earnings Data (2009–2025)
17 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$8M | -273.2% | -$8M | $-3.60 | -633.6% | -575.3% |
| 2024 | $5M | +173.8% | -$9M | $6.00 | 728.9% | -1312.8% |
| 2023 | -$7M | -12.1% | -$10M | $-16.80 | - | - |
| 2022 | -$6M | +29.4% | -$11M | $-30.80 | - | - |
| 2021 | -$8M | -492.1% | -$11M | $-80.00 | - | - |
| 2020 | -$1M | +95.6% | $2M | $-12.40 | - | - |
| 2019 | -$32M | -34.8% | -$23M | $-999999.00 | - | - |
| 2018 | -$23M | -136.2% | -$21M | $-999999.00 | - | - |
| 2017 | -$10M | -316.5% | -$7M | $-790280.00 | - | - |
| 2016 | -$2M | +8.9% | -$3M | $-282320.00 | - | - |
See SCNI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SCNI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SCNI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSCNI — Frequently Asked Questions
Quick answers to the most common questions about buying SCNI stock.
Is SCNI growing earnings?
SCNI EPS fell to $2.57, with earnings declining -160.0%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $4M.
What are SCNI's profit margins?
Scinai Immunotherapeutics Ltd. net margin is -633.6%, with operating margin at -575.3%. Below-average margins reflect competitive or cost pressures.
How consistent are SCNI's earnings?
SCNI earnings data spans 2009-2025. The declining earnings trend is -160.0% YoY. Historical data enables comparison across business cycles.